Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus
Abhinav Sharma(Government Medical College), Christopher B. Granger(Clinical Research Institute), Yves Rosenberg(National Institutes of Health), Todd Hobbs(Novo Nordisk (United States)), Hertzel C. Gerstein(McMaster University), John J.V. McMurray(University of Glasgow), Jane E.B. Reusch(United States Department of Veterans Affairs), Marc A. Pfeffer(Brigham and Women's Hospital), Jyothis T. George(Boehringer Ingelheim (China)), Rury R. Holman(University of Oxford), Francesca Lawson(Sanofi (United States)), Matthew T. Roe(Clinical Research Institute), Darren K. McGuire(Parkland Health & Hospital System), Lawrence A. Leiter(St. Michael's Hospital), Neha J. Pagidipati(Duke University), Jeffrey S. Riesmeyer(Eli Lilly (United States)), Stephen D. Wiviott(Brigham and Women's Hospital), Robert Temple(Center for Biologics Evaluation and Research), Dave DeMets(University of Wisconsin System), Robert M. Califf(Duke University), Jennifer B. Green
Cited by 108
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k